UPDATE: Piper Sandler Double Downgrades Humacyte (HUMA) to Underweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. BIIB
7. CMG
8. TENB
9. KLAC
10. ETSY

Go back to UPDATE: Piper Sandler Double Downgrades Humacyte (HUMA) to Underweight

Humacyte First Quarter 2022 Financial Results and Business Update

May 13, 2022 7:00 AM EDT

-- Human Acellular Vessels (HAVs) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries --

-- Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer --

 -- Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data --

-- Conference call and live webcast at 8:00 a.m. ET today --

DURHAM, N.C., May 13, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform... More